Study of the secretion of substance P, neurotensin and somatostatin in patients with cholelithiasis

What Was Tested

Researchers studied Somatostatin and Substance P in this clinical trial publication.

A comparative, case-control study on the pre- and postprandial release of three gastrointestinal peptides implicated in gallbladder motility has been carried out in humans in the attempt to determine their possible role in the pathogenesis of cholelithiasis.

Why It Was Studied

The levels of secretion of each hormone were compared in patients and healthy controls on an overall basis and in terms of sex, age and body weight.

Who Took Part

The abstract describes 20 subjects taking part.

PubMed indexes the participants as adults, both men and women.

How the Study Was Run

Plasma substance P, neurotensin and somatostatin were measured by means of RIA-I125 in basal fasting conditions and 30, 60 and 90 minutes after the oral intake of a semiliquid mixed meal.

What Was Measured

The levels of secretion of each hormone were compared in patients and healthy controls on an overall basis and in terms of sex, age and body weight.

The subject headings attached to it are Case-Control Studies, Cholelithiasis, Neurotensin, Somatostatin and Substance P.

What This Means in Plain Language

This is a clinical trial of Somatostatin and Substance P in 20 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1997 (Revista espanola de enfermedades digestivas), a journal based in Spain.

More context: the Somatostatin compound page and the Substance P compound page, all human trials.